Tilray: Will the Largest Canadian Pot Stock Outperform the TSX in 2021?

Tilray is the largest Canadian cannabis company in terms of revenue. But is this pot stock worth your money?

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

In May 2021, Tilray (TSX:TLRY)(NASDAQ:TLRY) merged with Aphria, thereby creating the largest Canadian cannabis company (in terms of sales) in the process. However, several Canadian companies, including Tilray, remain unprofitable due to rising competition as well as high inventory writedowns, among other factors. Alternatively, the marijuana industry should continue to expand in the upcoming decade, especially if the U.S. legalizes pot at the federal level.

Does this make it the right time to add Tilray stock to your portfolio?

Tilray and Aphria’s big-ticket acquisitions

Prior to the merger, both Tilray and Aphria acquired companies. Last November, Aphria bought U.S.-based craft beer maker SweetWater Brewing, which should accelerate its entry into the cannabis beverage market south of the border once marijuana is legalized. Similarly in October 2020, Tilray entered the cannabis derivatives market with a new line of edibles via its subsidiary High Park Holdings.

These acquisitions provide the combined entity the resources to compete with giants such as Canopy Growth and HEXO, which are rapidly expanding in Cannabis 2.0 space.

In Q4 of 2020, Tilray’s sales were up 20.5% year over year at US$57 million, and revenue rose 26% to US$210 million in 2020. It also reported an adjusted EBITDA of US$2.2 million compared to a loss of US$35.3 million in 2019. It was the first quarter where Tilray’s adjusted EBITDA was positive.

Aphria, however, has generated a positive adjusted EBITDA for seven consecutive quarters, which suggests the combined company should be profitable after the integration.

Both Tilray and Aphria aimed to gain traction in Europe, where the cannabis market is expected to touch US$37 billion by 2027, growing at an annual rate of almost 30% in the next seven years.

Aphria has a sizeable presence in Germany’s medical marijuana market due to its CC Pharma subsidiary, while Tilray has a licensed cannabis production facility in Portugal.

What’s next for investors?

Several analysts in Wall Street are bullish on Tilray’s long-term prospects. According to Jeffries analyst Owen Bennett, Tilray stock might rise to US$23 in the next 12 months due to its leadership position in Canada. Likewise, Pablo Zuanic from Cantor Fitzgerald has a price target of US$22 for TLRY and is optimistic about the company’s diversified revenue base and its geographic distribution.

Tilray stock is currently trading at US$18.1, valuing the company at a market cap of US$8.06 billion. Analysts tracking the stock expect sales to rise from US$562 million in 2021 to US$861 million in 2022. This expansion in the top line will allow the pot heavyweight to improve its loss per share from US$1.69 in 2021 to US$0.22 in 2022.

It means Tilray stock is trading at a forward price-to-2022-sales multiple of less than 10, making it cheaper to peers including Canopy Growth and Cronos Group.

Tilray ended Q1 with a cash balance of US$2.32 billion and US$1.72 billion in debt, providing the company with sufficient liquidity to improve profit margins over time, making it a good bet for investors with a high-risk appetite.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends HEXO Corp.

More on Cannabis Stocks

Retirement plan
Dividend Stocks

4 Stocks That Could Turn $100,000 Into $500,000 by the Time You Retire

Companies such as Brookfield Asset Management have the potential to consistently beat the broader markets and deliver stellar returns to…

Read more »

IMAGE OF A NOTEBOOK WITH TFSA WRITTEN ON IT
Cannabis Stocks

TFSA Investors: 2 U.S. Stocks I’m Never Selling

Canadians looking to diversify their portfolios and gain exposure to U.S. stocks can purchase shares of high-growth companies such as…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Canopy Growth Stock Climbed as Much as 20% on Monday

A glimmer of hope from the U.S. Congress may lead to renewed interest in marijuana investing.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Friday, July 15

A continued selloff in metals prices is likely to pressure the commodity-heavy TSX Composite benchmark at the open today.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy!

After selling off for years, Organigram stock now offers tonnes of value and is easily one of the best cannabis…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »